The termination of the ATM facility is a severe liquidity blow for a $2M market cap biotech with no clear path to revenue. Monitor for an immediate liquidity crisis, potential going-concern disclosure, or a distressed financing event (e.g., reverse split, toxic debt, or bankruptcy). The stock is likely to trade down sharply on this news.
Price Chart
Executive Summary
BTIG, LLC terminated the at-the-market (ATM) sales agreement with Matinas BioPharma, effective immediately. The agreement, which allowed MTNB to sell up to $50M in common stock, was terminated by BTIG with no penalties or expenses owed by the company. This removes a key capital-raising facility for a micro-cap biotech with a $2M market cap, significantly constraining its financing options.
Key Facts
- BTIG terminated the ATM sales agreement with Matinas BioPharma on July 23, 2026, effective immediately.
- The agreement allowed MTNB to sell up to $50,000,000 in common stock through BTIG.
- The company is not subject to any termination penalties or expenses related to the termination.
- Matinas BioPharma has a market cap of approximately $2M and zero analyst bullish ratings.
Financial Impact
Loss of access to up to $50M in at-the-market equity financing facility; no termination fees incurred.
Risk Factors
- Loss of primary equity capital-raising mechanism for a pre-revenue biotech
- Potential inability to fund operations or clinical programs
- Increased risk of distressed financing, reverse stock split, or delisting
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-034601 |
| Document: 0001493152-26-034601-index-headers.html | 0001493152-26-034601 |
| Document: 0001493152-26-034601-index.html | 0001493152-26-034601 |
| Document: 0001493152-26-034601.txt | 0001493152-26-034601 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | 8-K | $2.53 $1.66 | ▼ −34.39% | ▼ −34.36% | $1.80 (−28.85%) |
Sep 16, 2026 5w ago | 8-K | $0.1630 $0.1613 | ▼ −1.02% | ▼ −2.23% | $1.80 (+1004.29%) |
Sep 4, 2026 7w ago | 8-K | $0.1820 $3.01 | ▼ −1553.85% | ▼ −1552.13% | $1.80 (−889.01%) |
Aug 25, 2026 9w ago | 425 | $0.1973 $0.1750 | ▲ +11.30% | ▲ +12.28% | $1.80 (−812.32%) |
Jul 30, 2026 12w ago | 425 | $0.3174 $0.2000 | ▲ +36.99% | ▲ +40.95% | $1.80 (−467.11%) |
Jul 24, 2026 13w ago | 8-K | $0.3320 $0.1965 | ▲ +40.81% | ▲ +44.11% | $1.80 (−442.17%) |
Jul 13, 2026 15w ago | 425 | $0.4800 $0.2690 | ▲ +43.96% | ▲ +47.14% | $1.80 (−275.00%) |
Jul 13, 2026 15w ago | 8-K | $0.4800 $0.2690 | ▲ +43.96% | ▲ +47.14% | $1.80 (−275.00%) |
Jun 26, 2026 17w ago | 8-K | $0.6640 $0.2414 | ▲ +63.64% | ▲ +63.37% | $1.80 (−171.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers